-
公开(公告)号：KR1020130137858A
公开(公告)日：2013-12-18
申请号：KR1020120061484
申请日：2012-06-08
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K48/005 , A23L33/13 , A23V2002/00 , A23V2200/324 , A61K2121/00
Abstract: The present invention relates to the pharmaceutical use of miR-29, which is used for preventing and treating immune diseases caused by abnormal immune response, and, more specifically, a composition containing the miR-29 as an active ingredient for preventing or treating immune diseases in the elderly. The miR-29 according to the present invention is very efficacious in inhibiting the differentiation into cytotoxic Th17 cells, which produces and secretes inflammatory cytokines, and activating immune regulatory T cells(Treg), which suppresses functions of abnormally activated immune cells and regulates immune responses, especially, more efficacious in case of treating the miR-29 to the elderly, thereby being useful in preventing and treating the immune diseases in the elderly caused by various kinds of abnormalities of the regulation of immune response such as autoimmune diseases, inflammatory diseases, and rejection of transplant as a pharmaceutical composition. The miR-29 is also stable in body and has no toxicity or side effect, thereby being used safely in case of long term use.
Abstract translation: 本发明涉及用于预防和治疗由免疫反应异常引起的免疫疾病的miR-29的药物用途，更具体地说，涉及含有miR-29作为预防或治疗免疫疾病的活性成分的组合物 在老人家 根据本发明的miR-29在抑制细胞毒性Th17细胞的分化中是非常有效的，其产生和分泌炎性细胞因子，并激活免疫调节性T细胞（Treg），其抑制异常活化的免疫细胞的功能并调节免疫应答 特别是在对老年人治疗miR-29的情况下更有效，从而可用于预防和治疗由各种免疫应答调节异常如自身免疫性疾病，炎性疾病等引起的老年人的免疫疾病， 并拒绝移植作为药物组合物。 miR-29在体内也是稳定的，没有毒性或副作用，因此在长期使用的情况下安全使用。
-
公开(公告)号：KR1020100043814A
公开(公告)日：2010-04-29
申请号：KR1020080103018
申请日：2008-10-21
Applicant: 가톨릭대학교 산학협력단
Abstract: PURPOSE: A pharmaceutical composition containing N-tosyl-L-phenylalanine chloromethyl ketone(TPCK) is provided to suppress NF-kappa(nuclear factor-kappa B) and expression of osteoclastogenic gene and to treat erosion of bone and cartilage. CONSTITUTION: A pharmaceutical composition for treating arthritis contains N-tosyl-L-phenylalanine chloromethyl ketone](TPCK). Arthritis is rheumatoid arthritis. The composition is formulated in the form of intraperitoneal administration. The composition suppresses erosion of bone and cartilage. The composition is used in the form of powder, granule, tablet, capsule, suspension liquid, emulsion, syrup, aerosol oral formulation, and sterilization injection solution.
Abstract translation: 目的：提供含有N-甲苯磺酰基-L-苯丙氨酸氯甲基酮（TPCK）的药物组合物，以抑制NF-κB（核因子κB）和破骨细胞发生基因的表达，并治疗骨和软骨的侵蚀。 构成：用于治疗关节炎的药物组合物含有N-甲苯磺酰基-L-苯丙氨酸氯甲基酮〕（TPCK）。 关节炎是类风湿关节炎。 组合物以腹膜内给药的形式配制。 该组合物抑制骨和软骨的侵蚀。 该组合物以粉末，颗粒，片剂，胶囊，悬浮液，乳剂，糖浆，气溶胶口服制剂和灭菌注射溶液的形式使用。
-
公开(公告)号：KR101426689B1
公开(公告)日：2014-08-08
申请号：KR1020110036053
申请日：2011-04-19
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/497 , A61K31/495 , A61K31/4164 , A61P37/00
Abstract: 본 발명은 Nutlin-3a 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물에 관한 것이다. 본 발명의 유효성분인 Nutlin-3a 화합물은 p53 과발현을 통해 IL-17의 발현을 억제시킴으로써 관절염 동물 모델에서 관절염을 개선시키는 효과 있으므로, 이를 유효성분으로 포함하는 본 발명의 조성물은 면역질환 예방 또는 치료에서 유용하게 사용될 수 있다.
-
公开(公告)号：KR1020120118978A
公开(公告)日：2012-10-30
申请号：KR1020110036667
申请日：2011-04-20
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/428 , A61K38/17 , A61P19/02 , A61P17/00
CPC classification number: A61K38/1758 , Y10S514/885 , Y10S530/868
Abstract: PURPOSE: A composition for preventing or treating immunization diseases including P53 is provided to suppress inflammatory cytokine IL-17 which causes the immunization diseases. CONSTITUTION: A composition for preventing or treating immunization diseases includes P53 as an active ingredient. The P53 has the activity of preventing or treating the immunization diseases through the formation inhibition of the inflammatory cytokine. The inflammatory cytokine is IL-17. The composition additionally includes substances for promoting the express of the p53 or for promoting the activity of protein. The composition for preventing or treating includes polynucleotide which codes the P53. The polynucleotide ciphering the p53 protein is provided in a recombinant vector type which is connected to a vector which expresses the same. The expression vector which expresses the P53 protein is a non-virus vector or a viral vector.
Abstract translation: 目的：提供用于预防或治疗包括P53在内的免疫疾病的组合物，以抑制引起免疫疾病的炎性细胞因子IL-17。 构成：用于预防或治疗免疫疾病的组合物包括P53作为活性成分。 P53具有通过炎性细胞因子的形成抑制来预防或治疗免疫疾病的活性。 炎性细胞因子是IL-17。 该组合物还包括用于促进p53表达或促进蛋白质活性的物质。 用于预防或治疗的组合物包括编码P53的多核苷酸。 加密p53蛋白质的多核苷酸以连接到表达相同的载体的重组载体类型提供。 表达P53蛋白的表达载体是非病毒载体或病毒载体。
-
公开(公告)号：KR101099021B1
公开(公告)日：2011-12-28
申请号：KR1020090035796
申请日：2009-04-24
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: 본 발명은 유럽종 포도(
Vitis vinifera )의 씨 추출물 및 약학적으로 허용가능한 담체를 포함하는 골관절염(osteoarthritis)의 예방 또는 치료용 약학 조성물을 제공한다.
유럽종 포도의 씨 추출물, 골관절염-
Patent Agency Ranking
公开(公告)号：KR101096574B1
公开(公告)日：2011-12-20
申请号：KR1020080126216
申请日：2008-12-12
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: 본 발명은 유럽종 포도(
Vitis vinifera )의 씨 추출물 및 약제학적으로 허용가능한 담체를 포함하는 골다공증의 예방 또는 치료용 약학 조성물을 제공한다.
유럽종 포도, 골다공증-
17.发明公开유럽종 포도의 씨 추출물의 제조방법 및 이를 함유하는 류마티스 관절염 예방 또는 치료용 약학 조성물 有权制备VITIS VINIFERA PIP萃取物和药物组合物的方法，用于预防或治疗包含其中的RHEUMATOID ARTHRITIS
公开(公告)号：KR1020110036031A
公开(公告)日：2011-04-06
申请号：KR1020110020720
申请日：2011-03-09
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract is provided to reduce acetone use and to prevent and treat rheumatic arthtritis. CONSTITUTION: A pharmaceutical composition for preventing or treating rheumatic arthritis contains Vitis vinifera seed extract and pharmaceutically acceptable carrier thereof. The extract is obtained by pulverizing Vitis vinifera seeds, extracting the seeds with a mixture solvent of acetone and water, removing acetone and saturating sodium chloride, extracting liquid with ethyl acetate and concentrating, adding chloroform and filtering.
Abstract translation: 目的：提供含有葡萄种子提取物的药物组合物，以减少丙酮使用并预防和治疗风湿性关节炎。 构成：用于预防或治疗风湿性关节炎的药物组合物含有葡萄籽种子提取物及其药学上可接受的载体。 提取物通过粉化葡萄种子获得，用丙酮和水的混合溶剂萃取种子，除去丙酮和饱和氯化钠，用乙酸乙酯萃取液并浓缩，加入氯仿和过滤。
-
公开(公告)号：KR101004362B1
公开(公告)日：2010-12-28
申请号：KR1020100024699
申请日：2010-03-19
Applicant: 한국생명공학연구원 , 가톨릭대학교 산학협력단
Inventor： 박영우 , 조기원 , 유석호 , 유정 , 김동진 , 윤선하 , 송은정 , 이은경 , 오진미 , 조규원 , 조미라 , 김호연 , 박미경 , 오혜좌 , 박진실 , 우윤주
CPC classification number: C07K14/525 , C07K14/70575 , C07K2319/32 , Y10S514/814 , Y10S514/885 , Y10S514/886 , Y10S514/903
Abstract: PURPOSE: A TNFR2-TWEAKR fusion protein is provided to ensure antagonistic function to TNFR2 and TWEAK which is a cause of autoimmune arthritis and to reduce IL-17 secretion. CONSTITUTION: A composition for preventing and treating autoimmune disease contains fusion protein of a fragment having an extracellular region of TNFR2(Tumor necrosis factor receptor type 2) or TNFR2 and a fragment having an extracellular region of TWEAKR(TNF-related weak inducer of apoptosis receptor) protein or TWEAKR as an active ingredient. The extracellular region fragment of TNFR2 has a polypeptide having an amino acid sequence of sequence number 2. The fusion protein has an amino acid sequence of sequence number 1.
Abstract translation: 目的：提供TNFR2-TWEAKR融合蛋白，以确保TNFR2和TWEAK的拮抗作用，这是导致自身免疫性关节炎和降低IL-17分泌的原因。 构成：用于预防和治疗自身免疫性疾病的组合物含有具有TNFR2细胞外区域（2型肿瘤坏死因子受体）或TNFR2的片段的融合蛋白和具有TWEAKR胞外区域的片段（TNF相关的凋亡受体弱诱导剂 ）蛋白质或TWEAKR作为活性成分。 TNFR2的细胞外区片段具有序列号为2的氨基酸序列的多肽。融合蛋白具有序列号1的氨基酸序列。
-
19.发明公开인터루킨-27, 인터루킨-27-에프씨 융합단백질 및 그돌연변이들을 포함하는 자가면역 질환의 예방 및 치료용약학적 조성물 无效用于预防和治疗包含白细胞介素-27蛋白，IL-27-FC融合蛋白及其突变体的自身免疫性疾病的药物组合物
公开(公告)号：KR1020090038336A
公开(公告)日：2009-04-20
申请号：KR1020070103779
申请日：2007-10-15
Applicant: 가톨릭대학교 산학협력단 , 포항공과대학교 산학협력단
IPC: A61K38/20
CPC classification number: A61K38/20 , A61K38/1722 , C07K14/4717 , C07K14/54 , C12N15/62 , C12N15/63 , Y10S424/809 , Y10S424/81
Abstract: A pharmaceutical composition containing Interleukin-27, Il-27-Fc fusion protein and mutant thereof is provided to efficiently inhibit production of IL-17 and increase production of IFN-gamma by promoting differentiation of Th-1 in order to treat and prevent autoimmune diseases. A pharmaceutical composition for treatment and prevention of autoimmune diseases comprises Interleukin-27, Il-27-Fc fusion protein and mutant thereof. The Interleukin-27 is human-derived proteins. The pharmaceutical composition contains Il-27-Fc fusion protein wherein carboxyl terminal of the Interleukin-27 is coupled with amino terminal of immunoglobulin Fc and peptide. The immunoglobulin Fc is derived from one selected from the group consisting of IgG, IgA, IgM, IgE and IgD. The immunoglobulin Fc has a hinge site which can has one or more cysteins. The autoimmune diseases represent systemic lupus erythematosus, Sjogren syndrome, Hashimoto thyroiditis, rheumatoid arthritis, polymyositis, scleroderma, Addison disease, vitiligo, pernicious anemia, glomerulonephritis or pulmonary fibrosis.
Abstract translation: 提供了含有白细胞介素-27，II-27-Fc融合蛋白及其突变体的药物组合物，以有效抑制IL-17的产生并通过促进Th-1的分化来增加IFN-γ的产生，从而治疗和预防自身免疫疾病 。 用于治疗和预防自身免疫疾病的药物组合物包含白细胞介素-27，II-27-Fc融合蛋白及其突变体。 白细胞介素-27是人源性蛋白质。 药物组合物含有II-27-Fc融合蛋白，其中白细胞介素-27的羧基末端与免疫球蛋白Fc和肽的氨基末端偶联。 免疫球蛋白Fc来自选自IgG，IgA，IgM，IgE和IgD的一种。 免疫球蛋白Fc具有可以具有一个或多个半胱氨酸的铰链位点。 自身免疫性疾病代表系统性红斑狼疮，干燥综合征，桥本甲状腺炎，类风湿性关节炎，多发性肌炎，硬皮病，艾迪生病，白癜风，恶性贫血，肾小球性肾炎或肺纤维化。
-
公开(公告)号：KR101725571B1
公开(公告)日：2017-04-11
申请号：KR1020120063017
申请日：2012-06-13
Applicant: 가톨릭대학교 산학협력단
IPC: A61K48/00 , A61K31/4164 , A61K31/495
Abstract: 본발명은 MDM2 억제제를유효성분으로포함하는노화억제용조성물에관한것으로서, 보다구체적으로본 발명은 MDM2( mouse double minute 2) 억제제를유효성분으로포함하는노화또는노화관련질환의예방또는치료용조성물에관한것이다. 본발명에따른 MDM2 억제제는염증성사이토카인의생성및 이를분비하는세포독성 Th17 세포를억제하는효과가우수하고, 비정상적으로활성화된면역세포의기능을억제하고염증반응을제어하는특성을갖는면역조절 T 세포(Treg)의활성을증진시키는효과가우수하며, 나아가 STAT3의활성을억제할수 있는 SOCS3의발현을증가시키는활성이우수할뿐만아니라특히 MDM2 억제제를노인대상으로처리하였을때 노화억제효과가뛰어나각종면역반응과함께노화를억제할수 있는의약품의제조에유용하게사용할수 있는효과가있다.
Abstract translation: 本发明涉及一种组合物用于老化含有MDM2抑制剂作为有效成分，更具体地，本发明是MDM2（小鼠双微体2）用于预防或治疗老化或衰老相关疾病，包括抑制剂作为有效成分的组合物 Lt。 MDM2抑制剂根据本发明，具有如下性质的免疫调节抑制其分泌它们优异的炎性细胞因子，并且抑制了异常活跃的免疫细胞的功能，和控制炎症反应T中的生成和细胞毒性Th17细胞的效应 并增强细胞（Treg）优良的活性，并且进一步的老化抑制效果的效果优异的各种免疫以及抑制STAT3活性可以yiwoosu活性增加SOCS3的表达在不特别进行处理与老年受试者MDM2抑制剂 存在着可在药物可以抑制与反应沿老化制造中有用的效果。
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.031 seconds)
